CY1109400T1 - Αναστολεις μεταλλοπρωτεϊνασης μητρας - Google Patents
Αναστολεις μεταλλοπρωτεϊνασης μητραςInfo
- Publication number
- CY1109400T1 CY1109400T1 CY20091100090T CY091100090T CY1109400T1 CY 1109400 T1 CY1109400 T1 CY 1109400T1 CY 20091100090 T CY20091100090 T CY 20091100090T CY 091100090 T CY091100090 T CY 091100090T CY 1109400 T1 CY1109400 T1 CY 1109400T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- alkylaryl
- cor
- optionally substituted
- bond
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Macromonomer-Based Addition Polymer (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Soft Magnetic Materials (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Lubricants (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Περιγράφονται ενώσεις του τύπου (I): στον οποίο: το Α παριστάνει δεσμό, C1-6αλκύλιο ή CΗ&ίδια, CΗ-C1-4αλκύλιο, το Β παριστάνει δεσμό, Ο, S, SO, S02, CO, CR7R8, C02R14, CONR14R15, N(COR14)(COR15), N(S02R14)(COR15) ή NR14R15, το D παριστάνει δεσμό, ή C1-6αλκύλιο, το Ε παριστάνει υποκατεστημένο αρύλιο ή υποκατεστημένο ή μη υποκατεστημένο ετεροαρύλιο, το Q παριστάνει προαιρετικώς υποκατεστημένο 5- ή 6-μελή δακτύλιο αρυλίου ή ετεροαρυλίου, το Χ παριστάνει Ο, S, SO, S02, CO, CNR5, CNOR5, CNNR5R6, NR11 ή CR7R8, το Υ παριστάνει CR50R11, CR5SR11, NOR5, CR5NR6R11, SO, S02, CO, CNR5, CNOR5 ή CS, τα R1 και R1' το καθένα ανεξαρτήτως παριστάνει Η, C1-6αλκύλιο ή C1-4αλκυλαρύλιο, το R2 παριστάνει C02R12, CH20R12 ή CONR12R13, CONR120R13, NR12COR13, SR12, ΡΟ(ΟΗ)2, PONHR12 ή SONHR12, το R3 παριστάνει Η, C1-6αλκύλιο ή C1-4αλκυλαρύλιο, το R4 παριστάνει προαιρετικώς υποκατεστημένο αρύλιο ή ετεροαρύλιο, το Ζ παριστάνει δεσμό, CH2, Ο, S, SO, S02, NR5, OCR5R6, CR9R10O ή τα Ζ, R4 και Q σχηματίζουν μαζί μια προαιρετικώς υποκατεστημένη συμπυκνωμένη τρικυκλική ομάδα, τα R5 και R6 το καθένα ανεξαρτήτως παριστάνουν Η, C1-6αλκύλιο ή C1-4αλκυλαρύλιο, τα R7 και R8 το καθένα ανεξαρτήτως παριστάνουν Η, αλογονο, C1-6αλκύλιο ή C1-4αλκυλαρύλιο, τα R9 και R10 το καθένα ανεξαρτήτως παριστάνει Η, C1-6αλκύλιο προαιρετικώς υποκατεστημένο με αλογονο, κυανό, OR11 ή NR6R11, C1-4 αλκυλαρύλιο προαιρετικώς υποκατεστημένο με αλογονο, κυανο, OR11 ή NR6R11, OR11 ή, μαζί με το Ν με το οποίο συνδέονται, τα R9 και R10 σχηματίζουν ετεροκυκλική ομάδα, το R11 παριστάνει Η, C-16 αλκύλιο, C1-4 αλκυλαρύλιο ή COR5, τα R12 και R13 το καθένα ανεξαρτήτως παριστάνουν Η, C1-3 αλκύλιο, C1-3 αλκυλαρύλιο ή C1-3 αλκυλετεροαρύλιο ή, μαζί με την ομάδα με την οποία συνδέονται, τα R12 και R13 σχηματίζουν ένα ετεροκυκλικό δακτύλιο, τα R14 και R15 παριστάνουν το καθένα ανεξαρτήτως Η, C1-6 αλκύλιο, C1-4 αλκυλαρύλιο ή C1-4 αλκυλετεραρύλιο ή μαζί με την ομάδα με την οποία συνδέονται τα R14 και R15 σχηματίζουν ετεροκυκλική ή συμπυκνωμένη ετεροκυκλική ομάδα, και τα φυσιολογικώς λειτουργικά παράγωγα τους, μέθοδοι για την παρασκευή τους, φαρμακευτικές τυποποιήσεις που τις
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0321538.1A GB0321538D0 (en) | 2003-09-13 | 2003-09-13 | Therapeutically useful compounds |
| EP04765231A EP1663970B1 (en) | 2003-09-13 | 2004-09-10 | Matrix metalloproteinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1109400T1 true CY1109400T1 (el) | 2014-07-02 |
Family
ID=29227079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091100090T CY1109400T1 (el) | 2003-09-13 | 2009-01-27 | Αναστολεις μεταλλοπρωτεϊνασης μητρας |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US7601729B2 (el) |
| EP (3) | EP2295408A1 (el) |
| JP (3) | JP2007505081A (el) |
| KR (3) | KR20130079628A (el) |
| CN (1) | CN1849306B (el) |
| AT (2) | ATE502922T1 (el) |
| AU (1) | AU2004272280C1 (el) |
| BR (1) | BRPI0413791A (el) |
| CA (1) | CA2538315C (el) |
| CY (1) | CY1109400T1 (el) |
| DE (2) | DE602004017622D1 (el) |
| DK (1) | DK1663970T3 (el) |
| ES (2) | ES2362954T3 (el) |
| GB (1) | GB0321538D0 (el) |
| HK (1) | HK1092141A1 (el) |
| HR (1) | HRP20080668T3 (el) |
| IL (1) | IL173305A (el) |
| IS (2) | IS2622B (el) |
| MA (1) | MA28039A1 (el) |
| MX (1) | MXPA06002458A (el) |
| NO (1) | NO20060540L (el) |
| NZ (2) | NZ545211A (el) |
| PL (1) | PL1663970T3 (el) |
| PT (1) | PT1663970E (el) |
| RU (2) | RU2370488C2 (el) |
| SG (1) | SG145685A1 (el) |
| SI (1) | SI1663970T1 (el) |
| WO (1) | WO2005026120A1 (el) |
| ZA (1) | ZA200602070B (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0321538D0 (en) * | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| EP1856063B1 (en) * | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
| EA016567B1 (ru) | 2006-08-22 | 2012-05-30 | Ранбакси Лабораториз Лимитед | Ингибиторы матриксных металлопротеиназ |
| AU2013200728B2 (en) * | 2006-08-22 | 2014-12-18 | Sun Pharmaceutical Industries Limited | Matrix metalloproteinase inhibitors |
| EP2520561B1 (en) | 2007-06-08 | 2016-02-10 | MannKind Corporation | IRE-1A Inhibitors |
| FR2949463B1 (fr) * | 2009-08-26 | 2011-09-16 | Commissariat Energie Atomique | Inhibiteurs de mmp |
| BR112013002370A2 (pt) | 2010-07-30 | 2017-06-20 | Ranbaxy Laboratories Ltd | composto, composição farmacêutica e processo de preparação de um composto |
| JP2013540754A (ja) | 2010-09-24 | 2013-11-07 | ランバクシー ラボラトリーズ リミテッド | マトリックスメタロプロテイナーゼ阻害剤 |
| WO2014083229A1 (es) | 2012-11-28 | 2014-06-05 | Administración General De La Comunidad Autónoma De Euskadi | Uso de inhibidores de metaloproteasas en el tratamiento de enfermedades hepáticas poliquísticas |
| SI3413892T1 (sl) | 2016-02-12 | 2022-06-30 | Cytokinetics, Incorporated | Tetrahidroizokinolinski derivati |
| CN110769866B (zh) * | 2017-06-13 | 2022-07-29 | 爱惜康有限责任公司 | 具有可控愈合的外科缝合器 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4102024A1 (de) * | 1991-01-24 | 1992-07-30 | Thomae Gmbh Dr K | Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU2199195A (en) * | 1994-04-28 | 1995-11-29 | Uniroyal Chemical Company, Inc. | Fungicidal azole derivatives |
| BR9611555A (pt) * | 1995-12-06 | 1999-03-02 | Astra Pharma Prod | Compostos formulação farmacêutica utilização de um composto processo para tratamento de uma doença obstrutiva reversível das vias aéreas e para preparação do composto |
| DK0898566T3 (da) | 1996-04-19 | 2003-03-03 | Akzo Nobel Nv | Substituerede benzylaminer og anvendelse deraf til behandling af depression |
| HRP970246B1 (en) * | 1996-05-15 | 2002-04-30 | Bayer Ag | Substituted oxobutric acids as matrix metalloprotease inhibitors |
| US6870058B2 (en) | 1996-12-03 | 2005-03-22 | The Trustees Of The University Of Pennsylvania | Compounds which mimic the chemical and biological properties of discodermolide |
| US6242616B1 (en) | 1996-12-03 | 2001-06-05 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US6096904A (en) | 1996-12-03 | 2000-08-01 | The Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactone derivatives |
| US20050065353A1 (en) | 1996-12-03 | 2005-03-24 | Smith Amos B. | Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof |
| US5789605A (en) | 1996-12-03 | 1998-08-04 | Trustees Of The University Of Pennsylvania | Synthetic techniques and intermediates for polyhydroxy, dienyl lactones and mimics thereof |
| US5804581A (en) * | 1997-05-15 | 1998-09-08 | Bayer Corporation | Inhibition of matrix metalloproteases by substituted phenalkyl compounds |
| US6608052B2 (en) * | 2000-02-16 | 2003-08-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as anti-inflammatory agents |
| EP1381594A1 (en) * | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Urea compounds useful as anti-inflammatory agents |
| WO2004012663A2 (en) | 2002-08-01 | 2004-02-12 | Bristol-Myers Squibb Company | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme |
| AU2003290120A1 (en) * | 2002-11-19 | 2004-06-15 | Galderma Research & Development, S.N.C. | Biaromatic compounds which activate PPAR-Gama type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| GB0312654D0 (en) * | 2003-06-03 | 2003-07-09 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0314488D0 (en) | 2003-06-20 | 2003-07-23 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0319069D0 (en) | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| EP1856063B1 (en) | 2005-02-22 | 2012-01-25 | Ranbaxy Laboratories Limited | 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases |
| EA016567B1 (ru) | 2006-08-22 | 2012-05-30 | Ранбакси Лабораториз Лимитед | Ингибиторы матриксных металлопротеиназ |
-
2003
- 2003-09-13 GB GBGB0321538.1A patent/GB0321538D0/en not_active Ceased
-
2004
- 2004-09-10 AT AT08163972T patent/ATE502922T1/de not_active IP Right Cessation
- 2004-09-10 AU AU2004272280A patent/AU2004272280C1/en not_active Ceased
- 2004-09-10 JP JP2006525794A patent/JP2007505081A/ja active Pending
- 2004-09-10 BR BRPI0413791-4A patent/BRPI0413791A/pt not_active IP Right Cessation
- 2004-09-10 MX MXPA06002458A patent/MXPA06002458A/es active IP Right Grant
- 2004-09-10 EP EP10176905A patent/EP2295408A1/en not_active Withdrawn
- 2004-09-10 SI SI200431008T patent/SI1663970T1/sl unknown
- 2004-09-10 DE DE602004017622T patent/DE602004017622D1/de active Active
- 2004-09-10 KR KR1020137014317A patent/KR20130079628A/ko not_active Application Discontinuation
- 2004-09-10 KR KR1020127000264A patent/KR20120007566A/ko not_active Application Discontinuation
- 2004-09-10 SG SG200805432-2A patent/SG145685A1/en unknown
- 2004-09-10 DE DE602004031991T patent/DE602004031991D1/de active Active
- 2004-09-10 WO PCT/EP2004/010319 patent/WO2005026120A1/en active Application Filing
- 2004-09-10 AT AT04765231T patent/ATE413384T1/de active
- 2004-09-10 CA CA2538315A patent/CA2538315C/en not_active Expired - Fee Related
- 2004-09-10 US US10/571,443 patent/US7601729B2/en not_active Expired - Fee Related
- 2004-09-10 ES ES08163972T patent/ES2362954T3/es active Active
- 2004-09-10 PL PL04765231T patent/PL1663970T3/pl unknown
- 2004-09-10 DK DK04765231T patent/DK1663970T3/da active
- 2004-09-10 NZ NZ545211A patent/NZ545211A/en not_active IP Right Cessation
- 2004-09-10 KR KR1020067005114A patent/KR20060120648A/ko active Search and Examination
- 2004-09-10 CN CN200480026229.7A patent/CN1849306B/zh not_active Expired - Fee Related
- 2004-09-10 ES ES04765231T patent/ES2314436T3/es active Active
- 2004-09-10 EP EP04765231A patent/EP1663970B1/en active Active
- 2004-09-10 PT PT04765231T patent/PT1663970E/pt unknown
- 2004-09-10 RU RU2006106850/04A patent/RU2370488C2/ru not_active IP Right Cessation
- 2004-09-10 NZ NZ573479A patent/NZ573479A/en not_active IP Right Cessation
- 2004-09-10 EP EP08163972A patent/EP2042488B1/en active Active
-
2006
- 2006-01-23 IL IL173305A patent/IL173305A/en not_active IP Right Cessation
- 2006-01-26 IS IS8268A patent/IS2622B/is unknown
- 2006-02-02 NO NO20060540A patent/NO20060540L/no not_active Application Discontinuation
- 2006-03-10 ZA ZA200602070A patent/ZA200602070B/en unknown
- 2006-03-14 MA MA28873A patent/MA28039A1/fr unknown
- 2006-11-15 HK HK06112572.5A patent/HK1092141A1/xx not_active IP Right Cessation
-
2008
- 2008-11-07 US US12/266,767 patent/US8263602B2/en not_active Expired - Fee Related
- 2008-11-26 RU RU2008146479/04A patent/RU2008146479A/ru not_active Application Discontinuation
- 2008-12-19 HR HR20080668T patent/HRP20080668T3/xx unknown
-
2009
- 2009-01-27 CY CY20091100090T patent/CY1109400T1/el unknown
- 2009-08-19 IS IS8843A patent/IS8843A/is unknown
- 2009-09-01 US US12/551,892 patent/US8343986B2/en not_active Expired - Fee Related
-
2011
- 2011-06-14 JP JP2011132261A patent/JP2011231118A/ja not_active Withdrawn
-
2012
- 2012-01-25 JP JP2012012663A patent/JP2012107031A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109400T1 (el) | Αναστολεις μεταλλοπρωτεϊνασης μητρας | |
| ATE362910T1 (de) | Matrix metalloprotease inhibitoren | |
| BR0201697A (pt) | Compostos de alfa-aminoácid0, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
| SE8008680L (sv) | Basiska etrar, sett for deras framstellning och farmaceutiska beredningar innehallande dem | |
| EA200000431A2 (ru) | Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA200100090A2 (ru) | Новые пиперидин-4-сульфонамидные производные, способ их получения и содержащие их фармацевтические композиции | |
| HUP0201475A2 (hu) | Heteroarilamidin-, metilamidin- és guanidinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények | |
| EA200300044A1 (ru) | Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции | |
| BG106847A (en) | Substituted piperazine derivatives as mtp inhibitors | |
| DK1010698T3 (da) | Hidtil ukendte derivater af 1,2-dithiolan, fremgangsmåde til fremstiling deraf og farmaceutiske sammensætninger indeholdende dem | |
| EA200000530A1 (ru) | НОВЫЕ 19-НОРСТЕРОИДЫ, ЗАМЕЩЕННЫЕ В ПОЛОЖЕНИИ 11β, СПОСОБ И ПРОМЕЖУТОЧНЫЕ ПРОДУКТЫ ДЛЯ ИХ ПОЛУЧЕНИЯ, ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
| ATE239021T1 (de) | Metalloproteaseinhibitoren, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen | |
| EA200001077A3 (ru) | Новые соединения аминопирролина, способ их получения и содержащие их фармацевтические композиции | |
| DK0955310T3 (da) | Hidtil ukendte (3,4,7,8,9,10)-hexahydro-6,10-dioxo-6H-pyridazino[1,2-a][1,2]diazepin-1-carboxylsyrederivater, fremgangsmåde til fremstilling af disse og anvendelse af disse til fremstilling af lægemidler | |
| DK1188752T3 (da) | Fremgangsmåde til fremstilling af substitueret alkylaminderivat | |
| ES2058182T3 (es) | Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas. | |
| DK1240162T3 (da) | 3-imino-1,2-dithiolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse |